Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy.

Shinozaki, Masaru; O'Day, Steven J; Kitago, Minoru; Amersi, Farin; Kuo, Christine; Kim, Joseph; Wang, He-Jing; Hoon, Dave S B

Shinozaki, Masaru; O'Day, Steven J; Kitago, Minoru; Amersi, Farin; Kuo, Christine; Kim, Joseph; Wang, He-Jing; Hoon, Dave S B.

Affiliation

Shinozaki M; Department of Molecular Oncology, Division of Surgical Oncology, John Wayne Cancer Institute at Saint John's Health Center and The Angeles Clinic and Research Institute, Santa Monica, California 90404, USA.

Clin Cancer Res ; 13(7): 2068-74, 2007 Apr 01.

Article in En | MEDLINE | ID: mdl-17404088

Subject(s)

DNA Probes; DNA, Neoplasm/blood; Melanoma/blood; Proto-Oncogene Proteins B-raf/genetics; Skin Neoplasms/blood; Antineoplastic Agents/therapeutic use; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma/drug therapy; Melanoma/pathology; Middle Aged; Mutation; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Skin Neoplasms/drug therapy; Skin Neoplasms/pathology; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Skin Neoplasms / DNA, Neoplasm / DNA Probes / Proto-Oncogene Proteins B-raf / Melanoma Type of study: Diagnostic_studies / Prognostic_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2007 Type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google